托伐普坦辅助贝前列素钠在肺动脉高压所致心力衰竭患者中的应用效果

Effect of Tovastaptan assisted with Berprost Sodium in patients with heart failure caused by pulmonary hypertension

目的探讨托伐普坦辅助贝前列素钠在肺动脉高压所致心力衰竭患者中的应用效果。方法选取2020年6月至2021年1月九江市第一人民医院收治的60例肺动脉高压导致心力衰竭患者作为研究对象,按照随机投掷方法分为对照组(30例)与研究组(30例)。对照组采用基础治疗联合贝前列素钠治疗,研究组在对照组基础上加用托伐普坦治疗。比较两组患者的血钠、血钾、内分泌因子、血肌酐、不良反应等。结果观察组患者治疗后水肿消退时间和气促缓解时间、乏力改善时间均短于对照组,差异有统计学意义(P<0.05);治疗前,两组患者的血钾、血肌酐、血钠比较,差异无统计学意义(P>0.05);治疗后,两组患者血钾和血钠水平均高于治疗前,血肌酐均低于治疗前,且观察组患者的血肌酐低于对照组,血钠以及血钾水平高于对照组,差异均有统计学意义(P<0.05);两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05);治疗前,两组患者的左心室射血分数(LVEF)水平、氨基末端脑钠肽前体(NT-proBNP)比较,差异无统计学意义(P>0.05);治疗后,两组患者的LVEF水平均高于治疗前,NT-proBNP均低于治疗前,且观察组的NT-proBNP低于对照组,LVEF水平高于对照组,差异有统计学意义(P<0.05)。结论为肺动脉高压心力衰竭患者予以托伐普坦辅助贝前列素钠治疗时可有效提升心功能,改善症状缓解时间,无严重不良反应,生化指标逐步恢复正常。

Objective To investigate the effect of Tovastaptan assisted with Berprost Sodium in patients with heart failure caused by pulmonary hypertension.Methods A total of 60 patients with heart failure caused by pulmonary hypertension admitted to Jiujiang First People′s Hospital from June 2020 to January 2021 were selected as the research subjects,and they were divided into control group(30 cases)and research group(30 cases)according to random throwing method.The control group was treated with basic treatment combined with Beprost Sodium,and the study group was treated with Tovaptan on the basis of the control group.Blood sodium,blood potassium,endocrine factors,serum creatinine and adverse reactions were compared between the two groups.Results The disappearance time of edema,relief time of shortness of breath and improvement time of fatigue in the observation group were shorter than those in the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in serum potassium,creatinine and sodium between the two groups(P>0.05).After treatment,the serum potassium and sodium levels of the two groups were higher than those before treatment,and the serum creatinine was lower than before treatment,and the serum creatinine of the observation group was lower than that of the control group,and the serum sodium and potassium levels were higher than those of the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Before treatment,there were no significant differences in left ventricular ejection fraction(LVEF)and N-terminal pro brain natriuretic peptide(NT-proBNP)between the two groups(P>0.05).After treatment,LVEF levels of the two groups were higher than before treatment,NT-proBNP were lower than before treatment,and NT-proBNP of the observation group was lower than that of the control group,LVEF level was higher than that of the control group,the difference was statistically significant(P<0.05).Conclusion Tovastan combined with Berprost Sodium can effectively improve cardiac function,improve symptom relief time,no serious adverse reactions,and gradually return to normal biochemical indicators in patients with pulmonary hypertension heart failure.